Lipoprotein(a) in clinical practice: New perspectives from basic and translational science

References

• Nsaibia MJ, Mahmut A, Boulanger MC, et al. Autotaxin interacts with lipoprotein(a) and oxidized phospholipids in predicting the risk of calcific aortic valve stenosis in patients with coronary artery disease. J Intern Med. 2016;280:509–517.
   PubMed Web of Science ®Google Scholar
• Yeang C, Wilkinson MJ, Tsimikas S. Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis. Curr Opin Cardiol. 2016;31:440–450.
   PubMed Web of Science ®Google Scholar
• Kronenberg F. Human genetics and the causal role of lipoprotein(a) for various diseases. Cardiovasc Drugs Ther. 2016;30:87–100.
   PubMed Web of Science ®Google Scholar
• Emerging Risk Factors C, Erqou S, Kaptoge S, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302:412–423.
   PubMed Web of Science ®Google Scholar
• Emdin CA, Khera AV, Natarajan P, et al. Phenotypic characterization of genetically lowered human lipoprotein(a) levels. J Am Coll Cardiol. 2016;68:2761–2772.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844–2853.
   PubMed Web of Science ®Google Scholar
• Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69:692–711.
   PubMed Web of Science ®Google Scholar
• Verbeek R, Boekholdt SM, Stoekenbroek RM, et al. Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study. J Lipid Res. 2016;57:697–705.
   PubMed Web of Science ®Google Scholar
• Fless GM, Rolih CA, Scanu AM. Heterogeneity of human plasma lipoprotein (a). Isolation and characterization of the lipoprotein subspecies and their apoproteins. J Biol Chem. 1984;259:11470–11478.
   PubMed Web of Science ®Google Scholar
• Kronenberg F, Utermann G. Lipoprotein(a): resurrected by genetics. J Intern Med. 2013;273:6–30.
   PubMed Web of Science ®Google Scholar
• Berg K. A new serum type system in-man–the Lp system. Acta Pathol Microbiol Scand. 1963;59:369–382.
   PubMedGoogle Scholar
• Koschinsky ML, Marcovina SM. Lipoprotein(a). In: Ballantyne CM, editor. Clinical lipidology: a companion to Braunwald's heart disease. Philadelphia: Saunders Elsevier; 2009.p.130–143.
   Google Scholar
• Fless GM, ZumMallen ME, Scanu AM. Physicochemical properties of apolipoprotein(a) and lipoprotein(a) derived from the dissociation of human plasma lipoprotein (a). J Biol Chem. 1986;261:8712–8718.
   PubMed Web of Science ®Google Scholar
• Simons K, Ehnholm C, Renkonen O, et al. Characterization of the Lp(a) lipoprotein in human plasma. Acta Pathol Microbiol Scand B Microbiol Immunol. 1970;78:459–466.
   PubMedGoogle Scholar
• Koschinsky ML, Cote GP, Gabel B, et al. Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100. J Biol Chem. 1993;268:19819–19825.
   PubMed Web of Science ®Google Scholar
• Koschinsky ML, Marcovina SM. Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity. Curr Opin Lipidol. 2004;15:167–174.
   PubMed Web of Science ®Google Scholar
• McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330:132–137.
   PubMed Web of Science ®Google Scholar
• Guevara J Jr, Knapp RD, Honda S, et al. A structural assessment of the apo[a] protein of human lipoprotein[a]. Proteins. 1992;12:188–199.
   PubMed Web of Science ®Google Scholar
• Angles-Cano E, Rojas G. Apolipoprotein(a): structure-function relationship at the lysine-binding site and plasminogen activator cleavage site. Biol Chem. 2002;383:93–99.
   PubMed Web of Science ®Google Scholar
• Becker L, McLeod RS, Marcovina SM, et al. Identification of a critical lysine residue in apolipoprotein B-100 that mediates noncovalent interaction with apolipoprotein(a). J Biol Chem. 2001;276:36155–36162.
   PubMed Web of Science ®Google Scholar
• Sangrar W, Koschinsky ML. Characterization of the interaction of recombinant apolipoprotein(a) with modified fibrinogen surfaces and fibrin clots. Biochem Cell Biol. 2000;78:519–525.
   PubMed Web of Science ®Google Scholar
• Romagnuolo R, Marcovina SM, Boffa MB, et al. Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a). J Lipid Res. 2014;55:625–634.
   PubMed Web of Science ®Google Scholar
• Cho T, Romagnuolo R, Scipione C, et al. Apolipoprotein(a) stimulates nuclear translocation of beta-catenin: a novel pathogenic mechanism for lipoprotein(a). Mol Biol Cel. 2013;24:210–221.
   PubMed Web of Science ®Google Scholar
• Scanu AM, Miles LA, Fless GM, et al. Rhesus monkey lipoprotein(a) binds to lysine Sepharose and U937 monocytoid cells less efficiently than human lipoprotein(a). Evidence for the dominant role of Kringle 4(37). J Clin Invest. 1993;91:283–291.
   PubMed Web of Science ®Google Scholar
• Hancock MA, Boffa MB, Marcovina SM, et al. Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J Biol Chem. 2003;278:23260–23269.
   PubMed Web of Science ®Google Scholar
• Bergmark C, Dewan A, Orsoni A, et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res. 2008;49:2230–2239.
   PubMed Web of Science ®Google Scholar
• Scipione CA, Sayegh SE, Romagnuolo R, et al. Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a). J Lipid Res. 2015;56:2273–2285.
   PubMed Web of Science ®Google Scholar
• van der Valk FM, Bekkering S, Kroon J, et al. Oxidized phospholipids on lipoprotein (a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. Circulation. 2016;134:611–624.
   PubMed Web of Science ®Google Scholar
• Authors/Task Force M, Catapano AL, Graham I, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;253:281–344.
   PubMed Web of Science ®Google Scholar
• Stefanutti C, Julius U, Watts GF, et al. Toward an international consensus-integrating lipoprotein apheresis and new lipid-lowering drugs. J Clin Lipidol. 2017;11:858–871 e3.
   PubMed Web of Science ®Google Scholar
• Dati F, Tate JR, Marcovina SM, et al. First WHO/IFCC international reference reagent for lipoprotein(a) for immunoassay-Lp(a) SRM 2B. Clin Chem Lab Med. 2004;42:670–676.
   PubMed Web of Science ®Google Scholar
• Marcovina SM, Albers JJ, Scanu AM, et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem. 2000;46:1956–1967.
   PubMed Web of Science ®Google Scholar
• Marcovina SM, Koschinsky ML, Albers JJ, et al. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. Clin Chem. 2003;49:1785–1796.
   PubMed Web of Science ®Google Scholar
• Marcovina SM, Albers JJ. Lipoprotein (a) measurements for clinical application. J Lipid Res. 2016;57:526–537.
   PubMed Web of Science ®Google Scholar
• Lassman ME, McLaughlin TM, Zhou H, et al. Simultaneous quantitation and size characterization of apolipoprotein(a) by ultra-performance liquid chromatography/mass spectrometry. Rapid Commun Mass Spectrom. 2014;28:1101–1106.
   PubMed Web of Science ®Google Scholar
• Marcovina SM, Zhang ZH, Gaur VP, et al. Identification of 34 apolipoprotein(a) isoforms: differential expression of apolipoprotein(a) alleles between American blacks and whites. Biochem Biophys Res Commun. 1993;191:1192–1196.
   PubMed Web of Science ®Google Scholar
• Boffa MB, Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem. 2004;37:333–343.
   PubMed Web of Science ®Google Scholar
• Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301:2331–2339.
   PubMed Web of Science ®Google Scholar
• Kamstrup PR, Benn M, Tybjaerg-Hansen A, et al. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation. 2008;117:176–184.
   PubMed Web of Science ®Google Scholar
• Lopez S, Buil A, Ordonez J, et al. Genome-wide linkage analysis for identifying quantitative trait loci involved in the regulation of lipoprotein a (Lp(a)) levels. Eur J Hum Genet. 2008;16:1372–1379.
   PubMed Web of Science ®Google Scholar
• Zabaneh D, Kumari M, Sandhu M, et al. Meta analysis of candidate gene variants outside the LPA locus with Lp(a) plasma levels in 14,500 participants of six White European cohorts. Atherosclerosis. 2011;217:447–451.
   PubMed Web of Science ®Google Scholar
• Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361:2518–2528.
   PubMed Web of Science ®Google Scholar
• Chasman DI, Shiffman D, Zee RY, et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis. 2009;203:371–376.
   PubMed Web of Science ®Google Scholar
• Arai K, Luke MM, Koschinsky ML, et al. The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles. Atherosclerosis. 2010;209:498–503.
   PubMed Web of Science ®Google Scholar
• Rowland CM, Pullinger CR, Luke MM, et al. Lipoprotein (a), LPA Ile4399Met, and fibrin clot properties. Thromb Res. 2014;133:863–867.
   PubMed Web of Science ®Google Scholar
• Scipione CA, McAiney JT, Simard DJ, et al. Characterization of the I4399M variant of apolipoprotein(a): implications for altered prothrombotic properties of lipoprotein(a). J Thromb Haemost. 2017;15:1834–1844.
   PubMed Web of Science ®Google Scholar
• Luke MM, Kane JP, Liu DM, et al. A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol. 2007;27:2030–2036.
   PubMedGoogle Scholar
• Thanassoulis G. Lipoprotein (a) in calcific aortic valve disease: from genomics to novel drug target for aortic stenosis. J Lipid Res. 2016;57:917–924.
   PubMed Web of Science ®Google Scholar
• Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368:503–512.
   PubMed Web of Science ®Google Scholar
• Zewinger S, Kleber ME, Tragante V, et al. Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. Lancet Diabetes Endocrinol. 2017;5:534–543.
   PubMed Web of Science ®Google Scholar
• Erqou S, Thompson A, Di Angelantonio E, et al. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol. 2010;55:2160–2167.
   PubMed Web of Science ®Google Scholar
• Saleheen D, Haycock PC, Zhao W, et al. Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis. Lancet Diabetes Endocrinol. 2017;5:524–533.
   PubMed Web of Science ®Google Scholar
• Kronenberg F. Causes and consequences of lipoprotein(a) abnormalities in kidney disease. Clin Exp Nephrol. 2014;18:234–237.
   PubMed Web of Science ®Google Scholar
• Kronenberg F, Konig P, Neyer U, et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol. 1995;6:110–120.
   PubMed Web of Science ®Google Scholar
• Kronenberg F, Lingenhel A, Lhotta K, et al. The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome. Kidney Int. 2004;65:606–612.
   PubMed Web of Science ®Google Scholar
• Azrolan N, Brown CD, Thomas L, et al. Cyclosporin A has divergent effects on plasma LDL cholesterol (LDL-C) and lipoprotein(a) [Lp(a)] levels in renal transplant recipients. Evidence for renal involvement in the maintenance of LDL-C and the elevation of Lp(a) concentrations in hemodialysis patients. Arterioscler Thromb. 1994;14:1393–1398.
   PubMedGoogle Scholar
• Kerschdorfer L, Konig P, Neyer U, et al. Lipoprotein(a) plasma concentrations after renal transplantation: a prospective evaluation after 4 years of follow-up. Atherosclerosis. 1999;144:381–391.
   PubMed Web of Science ®Google Scholar
• von Ahsen N, Helmhold M, Eisenhauer T, et al. Decrease in lipoprotein(a) after renal transplantation is related to the glucocorticoid dose. Eur J Clin Invest. 1996;26:668–675.
   PubMed Web of Science ®Google Scholar
• Glader CA, Birgander LS, Soderberg S, et al. Lipoprotein(a), chlamydia pneumoniae, leptin and tissue plasminogen activator as risk markers for valvular aortic stenosis. Eur Heart J. 2003;24:198–208.
   PubMed Web of Science ®Google Scholar
• Bozbas H, Yildirir A, Atar I, et al. Effects of serum levels of novel atherosclerotic risk factors on aortic valve calcification. J Heart Valve Dis. 2007;16:387–393.
   PubMed Web of Science ®Google Scholar
• Gotoh T, Kuroda T, Yamasawa M, et al. Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study). Am J Cardiol. 1995;76:928–932.
   PubMed Web of Science ®Google Scholar
• Capoulade R, Chan KL, Yeang C, et al. Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis. J Am Coll Cardiol. 2015;66:1236–1246.
   PubMed Web of Science ®Google Scholar
• Arsenault BJ, Boekholdt SM, Dube MP, et al. Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort. Circ Cardiovasc Genet. 2014;7:304–310.
   PubMed Web of Science ®Google Scholar
• Langsted A, Varbo A, Kamstrup PR, et al. Elevated lipoprotein(a) does not cause low-grade inflammation despite causal association with aortic valve stenosis and myocardial infarction: A study of 100,578 individuals from the general population. J Clin Endocrinol Metab. 2015;100:2690–2699.
   PubMed Web of Science ®Google Scholar
• Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 2014;63:470–477.
   PubMed Web of Science ®Google Scholar
• Marcucci R, Liotta AA, Cellai AP, et al. Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism. Am J Med. 2003;115:601–605.
   PubMed Web of Science ®Google Scholar
• Nowak-Gottl U, Junker R, Hartmeier M, et al. Increased lipoprotein(a) is an important risk factor for venous thromboembolism in childhood. Circulation. 1999;100:743–748.
   PubMed Web of Science ®Google Scholar
• Nowak-Gottl U, Strater R, Heinecke A, et al. Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood. Blood. 1999;94:3678–3682.
   PubMed Web of Science ®Google Scholar
• Nowak-Gottl U, Schobess R, Kurnik K, et al. Elevated lipoprotein(a) concentration is an independent risk factor of venous thromboembolism. Blood. 2002;99:3476–3477.
   PubMedGoogle Scholar
• Sticchi E, Magi A, Kamstrup PR, et al. Apolipoprotein(a) Kringle-IV type 2 copy number variation is associated with venous thromboembolism. PLoS One. 2016;11:e0149427.
   PubMed Web of Science ®Google Scholar
• Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis. Arterioscler Thromb Vasc Biol. 2012;32:1732–1741.
   PubMed Web of Science ®Google Scholar
• Danik JS, Buring JE, Chasman DI, et al. Lipoprotein(a), polymorphisms in the LPA gene, and incident venous thromboembolism among 21483 women. J Thromb Haemost. 2013;11:205–208.
   PubMed Web of Science ®Google Scholar
• Helgadottir A, Gretarsdottir S, Thorleifsson G, et al. Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J Am Coll Cardiol. 2012;60:722–729.
   PubMed Web of Science ®Google Scholar
• Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004;109:III27–III32.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Hirata M, Yoshikawa Y, et al. Role of macrophages in atherosclerosis. Sequential observations of cholesterol-induced rabbit aortic lesion by the immunoperoxidase technique using monoclonal antimacrophage antibody. Lab Inves.t 1985;53:80–90.
   PubMed Web of Science ®Google Scholar
• Kita T, Kume N, Minami M, et al. Role of oxidized LDL in atherosclerosis. Ann N Y Acad Sci. 2001;47:199–205.
   Google Scholar
• Takami S, Yamashita S, Kihara S, et al. Lipoprotein(a) enhances the expression of intercellular adhesion molecule-1 in cultured human umbilical vein endothelial cells. Circulation. 1998;97:721–728.
   PubMed Web of Science ®Google Scholar
• Allen S, Khan S, Tam S, et al. Expression of adhesion molecules by lp(a): a potential novel mechanism for its atherogenicity. FASEB J. 1998;12:1765–1776.
   PubMed Web of Science ®Google Scholar
• Zhao SP, Xu DY. Oxidized lipoprotein(a) enhanced the expression of P-selectin in cultured human umbilical vein endothelial cells. Thromb Res. 2000;100:501–510.
   PubMed Web of Science ®Google Scholar
• Zhao SP, Xu DY. Oxidized lipoprotein(a) increases the expression of platelet-derived growth factor-B in human umbilical vein endothelial cells. Clin Chim Acta. 2000;296:121–133
   PubMed Web of Science ®Google Scholar
• Sotiriou SN, Orlova VV, Al-Fakhri N, et al. Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin. FASEB J. 2006;20:559–561.
   PubMed Web of Science ®Google Scholar
• Cho T, Jung Y, Koschinsky ML. Apolipoprotein(a), through its strong lysine-binding site in KIV10, mediates increased endothelial cell contraction and permeability via a Rho/Rho Kinase/MYPT1-dependent pathway. J Biol Chem. 2008;283:30503–30512.
   PubMed Web of Science ®Google Scholar
• Liu L, Craig AW, Meldrum HD, et al. Apolipoprotein(a) stimulates vascular endothelial cell growth and migration and signals through integrin alphaVbeta3. Biochem J. 2009;18:325–336.
   Google Scholar
• Liu L, Boffa MB, Koschinsky ML. Apolipoprotein(a) inhibits in vitro tube formation in endothelial cells: identification of roles for Kringle V and the plasminogen activation system. PLoS One. 2013;8:e52287.
   PubMed Web of Science ®Google Scholar
• O'Neil CH, Boffa MB, Hancock MA, et al. Stimulation of vascular smooth muscle cell proliferation and migration by apolipoprotein(a) is dependent on inhibition of transforming growth factor-beta activation and on the presence of Kringle IV type 9. J Biol Chem. 2004;279:55187–55195.
   PubMed Web of Science ®Google Scholar
• Grainger DJ, Kirschenlohr HL, Metcalfe JC, et al. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science. 1993;260:1655–1658.
   PubMed Web of Science ®Google Scholar
• Grainger DJ, Kemp PR, Liu AC, et al. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. Nature. 1994370:460–462.
   PubMed Web of Science ®Google Scholar
• Riches K, Franklin L, Maqbool A, et al. Apolipoprotein(a) acts as a chemorepellent to human vascular smooth muscle cells via integrin αVβ3 and RhoA/ROCK-mediated mechanisms. Int J Biochem Cell Biol. 2013;45:1776–1783.
   PubMed Web of Science ®Google Scholar
• Ichikawa T, Unoki H, Sun H, et al. Lipoprotein(a) promotes smooth muscle cell proliferation and dedifferentiation in atherosclerotic lesions of human apo(a) transgenic rabbits. Am J Pathol. 2002;160:227–236.
   PubMed Web of Science ®Google Scholar
• Dangas G, Mehran R, Harpel PC, et al. Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. J Am Coll Cardiol. 1998;32:2035–2042.
   PubMed Web of Science ®Google Scholar
• Fefer P, Tsimikas S, Segev A, et al. The role of oxidized phospholipids, lipoprotein (a) and biomarkers of oxidized lipoproteins in chronically occluded coronary arteries in sudden cardiac death and following successful percutaneous revascularization. Cardiovasc Revasc Med. 2012;13:11–19.
   PubMedGoogle Scholar
• Leibundgut G, Witztum JL, Tsimikas S. Oxidation-specific epitopes and immunological responses: Translational biotheranostic implications for atherosclerosis. Curr Opin Pharmacol. 2013;13:168–179.
   PubMed Web of Science ®Google Scholar
• Haberland ME, Fless GM, Scanu AM, et al. Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocyte-macrophages. J Biol Chem. 1992;267:4143–4151.
   PubMed Web of Science ®Google Scholar
• Edelstein C, Pfaffinger D, Hinman J, et al. Lysine-phosphatidylcholine adducts in Kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a). J Biol Chem. 2003;278:52841–52847.
   PubMed Web of Science ®Google Scholar
• Leibundgut G, Scipione C, Yin HY, et al. Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). J Lipid Res. 2013;54:2815–2830.
   PubMed Web of Science ®Google Scholar
• Orso E, Schmitz G. Lipoprotein(a) and its role in inflammation, atherosclerosis and malignancies. Clin Res Cardiol Suppl. 2017;12:31–37.
   PubMedGoogle Scholar
• Seimon TA, Nadolski MJ, Liao X, et al. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab. 2010;12:467–482.
   PubMed Web of Science ®Google Scholar
• Haque NS, Zhang X, French DL, et al. CC chemokine I-309 is the principal monocyte chemoattractant induced by apolipoprotein(a) in human vascular endothelial cells. Circulation. 2000;102:786–792.
   PubMed Web of Science ®Google Scholar
• Klezovitch O, Edelstein C, Scanu AM. Stimulation of Interleukin-8 production in human THP-1 macrophages by apolipoprotein(a): evidence for a critical involvement of elements in its c-terminal domain. J Biol Chem. 2001;276:46864–46869.
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Duff GW, Berger PB, et al. Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a). J Am Coll Cardiol. 2014;63:1724–1734.
   PubMed Web of Science ®Google Scholar
• Bouchareb R, Mahmut A, Nsaibia MJ, et al. Autotaxin derived from lipoprotein(a) and valve interstitial cells promotes inflammation and mineralization of the aortic valve. Circulation. 2015;132:677–690.
   PubMed Web of Science ®Google Scholar
• Karabina SA, Elisaf MC, Goudevenos J, et al. PAF-acetylhydrolase activity of Lp(a) before and during Cu(2+)-induced oxidative modification in vitro. Atherosclerosis. 1996;125:121–134.
   PubMed Web of Science ®Google Scholar
• Blencowe C, Hermetter A, Kostner GM, et al. Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein (a) in comparison with low density lipoprotein. J Biol Chem. 1995;270:31151–31157.
   PubMed Web of Science ®Google Scholar
• Noto H, Hara M, Karasawa K, et al. Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress. Arterioscler Thromb Vasc Biol. 2003;23:829–835.
   PubMed Web of Science ®Google Scholar
• Tsironis LD, Katsouras CS, Lourida ES, et al. Reduced PAF-acetylhydrolase activity associated with Lp(a) in patients with coronary artery disease. Atherosclerosis. 2004;177:193–201.
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Tsironis LD, Tselepis AD. New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2007;27:2094–2099.
   PubMed Web of Science ®Google Scholar
• Miles LA, Fless GM, Levin EG, et al. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature. 1989;25339:301–303.
   PubMed Web of Science ®Google Scholar
• Hajjar KA, Gavish D, Breslow JL, et al. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 1989;339:303–305.
   PubMed Web of Science ®Google Scholar
• Etingin OR, Hajjar DP, Hajjar KA, et al. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem. 1991;266:2459–2465.
   PubMed Web of Science ®Google Scholar
• Buechler C, Ullrich H, Ritter M, et al. Lipoprotein (a) up-regulates the expression of the plasminogen activator inhibitor 2 in human blood monocytes. Blood. 2001;97:981–986.
   PubMed Web of Science ®Google Scholar
• Levin EG, Miles LA, Fless GM, et al. Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells. Arterioscler Thromb. 1994;14:438–442.
   PubMed Web of Science ®Google Scholar
• Feric NT, Boffa MB, Johnston SM, et al. Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen: a novel mechanism for lipoprotein(a)-mediated inhibition of plasminogen activation. J Thromb Haemost. 2008;6:2113–2120.
   PubMed Web of Science ®Google Scholar
• Sangrar W, Gabel BR, Boffa MB, et al. The solution phase interaction between apolipoprotein(a) and plasminogen inhibits the binding of plasminogen to a plasmin-modified fibrinogen surface. Biochemistry. 1997;36:10353–10363.
   PubMed Web of Science ®Google Scholar
• Biemond BJ, Friederich PW, Koschinsky ML, et al. Apolipoprotein(a) attenuates endogenous fibrinolysis in the rabbit jugular vein thrombosis model in vivo. Circulation. 1997;96:1612–1615.
   PubMed Web of Science ®Google Scholar
• Palabrica TM, Liu AC, Aronovitz MJ, et al. Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nat Med. 1995;1:256–259.
   PubMed Web of Science ®Google Scholar
• Sha J, McCullough B, Hart E, et al. Apo(a) promotes thrombosis in a vascular injury model by a mechanism independent of plasminogen. J Thromb Haemost. 2005;3:2281–2289.
   PubMed Web of Science ®Google Scholar
• Caplice NM, Panetta C, Peterson TE, et al. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood. 2001;98:2980–2987.
   PubMed Web of Science ®Google Scholar
• Broze GJ, Jr, Warren LA, Novotny WF, et al. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood. 1988;71:335–343.
   PubMed Web of Science ®Google Scholar
• Desai K, Bruckdorfer KR, Hutton RA, et al. Binding of apoE-rich high density lipoprotein particles by saturable sites on human blood platelets inhibits agonist-induced platelet aggregation. J Lipid Res. 1989;30:831–840.
   PubMed Web of Science ®Google Scholar
• Ezratty A, Simon DI, Loscalzo J. Lipoprotein(a) binds to human platelets and attenuates plasminogen binding and activation. Biochemistry. 1993;32:4628–4633.
   PubMed Web of Science ®Google Scholar
• Henriksson P, Angelin B, Berglund L. Hormonal regulation of serum Lp (a) levels. Opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma. J Clin Invest. 1992;89:1166–1171.
   PubMed Web of Science ®Google Scholar
• Kim CJ, Jang HC, Cho DH, et al. Effects of hormone replacement therapy on lipoprotein(a) and lipids in postmenopausal women. Arterioscler Thromb. 1994;14:275–281.
   PubMed Web of Science ®Google Scholar
• Soma M, Fumagalli R, Paoletti R, et al. Plasma Lp(a) concentration after oestrogen and progestagen in postmenopausal women. Lancet. 1991;337:612.
   PubMed Web of Science ®Google Scholar
• Taskinen MR, Puolakka J, Pyorala T, et al. Hormone replacement therapy lowers plasma Lp(a) concentrations. Comparison of cyclic transdermal and continuous estrogen-progestin regimens. Arterioscler Thromb Vasc Biol. 1996;16:1215–1221.
   PubMed Web of Science ®Google Scholar
• Zysow BR, Kauser K, Lawn RM, et al. Effects of estrus cycle, ovariectomy, and treatment with estrogen, tamoxifen, and progesterone on apolipoprotein(a) gene expression in transgenic mice. Arterioscler Thromb Vasc Biol. 1997;17:1741–1745.
   PubMed Web of Science ®Google Scholar
• Wade DP, Clarke JG, Lindahl GE, et al. 5' control regions of the apolipoprotein(a) gene and members of the related plasminogen gene family. Proc Natl Acad Sci USA. 1993;90:1369–1373.
   PubMed Web of Science ®Google Scholar
• Lawn RM. The apolipoprotein(a) gene: characterization of 5' flanking regions and expression in transgenic mice. Chem Phys Lipids. 1994;67–68:19–23.
   PubMed Web of Science ®Google Scholar
• Chennamsetty I, Claudel T, Kostner KM, et al. Farnesoid X receptor represses hepatic human APOA gene expression. J Clin Invest. 2011;121:3724–3734.
   PubMed Web of Science ®Google Scholar
• Neele DM, de Wit EC, Princen HM. Insulin suppresses apolipoprotein(a) synthesis by primary cultures of cynomolgus monkey hepatocytes. Diabetologia. 1999;42:41–44.
   PubMed Web of Science ®Google Scholar
• Ding L, Song A, Dai M, et al. Serum lipoprotein (a) concentrations are inversely associated with T2D, prediabetes, and insulin resistance in a middle-aged and elderly Chinese population. J Lipid Res. 2015;56:920–926.
   PubMed Web of Science ®Google Scholar
• Mora S, Kamstrup PR, Rifai N, et al. Lipoprotein(a) and risk of type 2 diabetes. Clin Chem. 2010;56:1252–1260.
   PubMed Web of Science ®Google Scholar
• White AL, Hixson JE, Rainwater DL, et al. Molecular basis for “null” lipoprotein(a) phenotypes and the influence of apolipoprotein(a) size on plasma lipoprotein(a) level in the baboon. J Biol Chem. 1994;269:9060–9066.
   PubMed Web of Science ®Google Scholar
• White AL, Guerra B, Wang J, et al. Presecretory degradation of apolipoprotein [a] is mediated by the proteasome pathway. J Lipid Res. 1999;40:275–286.
   PubMed Web of Science ®Google Scholar
• White AL, Rainwater DL, Lanford RE. Intracellular maturation of apolipoprotein[a] and assembly of lipoprotein[a] in primary baboon hepatocytes. J Lipid Res. 1993;34:509–517.
   PubMed Web of Science ®Google Scholar
• Berglund L, Ramakrishnan R. Lipoprotein(a): an elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol. 2004;24:2219–2226.
   PubMed Web of Science ®Google Scholar
• Rubin J, Paultre F, Tuck CH, et al. Apolipoprotein [a] genotype influences isoform dominance pattern differently in African Americans and Caucasians. J Lipid Res. 2002;43:234–244.
   PubMed Web of Science ®Google Scholar
• Lee SR, Prasad A, Choi YS, et al. LPA Gene, ethnicity, and cardiovascular events. Circulation. 2017;135:251–263.
   PubMed Web of Science ®Google Scholar
• Cox LA, Jett C, Hixson JE. Molecular basis of an apolipoprotein[a] null allele: a splice site mutation is associated with deletion of a single exon. J Lipid Res. 1998;39:1319–1326.
   PubMed Web of Science ®Google Scholar
• Ogorelkova M, Gruber A, Utermann G. Molecular basis of congenital lp(a) deficiency: a frequent apo(a) 'null' mutation in caucasians. Hum Mol Genet. 1999;8:2087–2096.
   PubMed Web of Science ®Google Scholar
• Gries A, Nimpf J, Nimpf M, et al. Free and apo B-associated Lpa-specific protein in human serum. Clin Chim Acta. 1987;164:93–100.
   PubMed Web of Science ®Google Scholar
• Becker L, Cook PM, Wright TG, et al. Quantitative evaluation of the contribution of weak lysine-binding sites present within apolipoprotein(a) Kringle IV types 6-8 to lipoprotein(a) assembly. J Biol Chem. 2004;279:2679–2688.
   PubMed Web of Science ®Google Scholar
• Gabel BR, May LF, Marcovina SM, et al. Lipoprotein(a) assembly: quantitative assessment of the role of apo(a) Kringle IV types 2-10 in particle formation. Arterioscler Thromb Vasc Biol. 1996;16:1559–1567.
   PubMed Web of Science ®Google Scholar
• Becker L, Nesheim ME, Koschinsky ML. Catalysis of covalent Lp(a) assembly: evidence for an extracellular enzyme activity that enhances disulfide bond formation. Biochemistry. 2006;45:9919–9928.
   PubMed Web of Science ®Google Scholar
• Nassir F, Bonen DK, Davidson NO. Apolipoprotein(a) synthesis and secretion from hepatoma cells is coupled to triglyceride synthesis and secretion. J Biol Chem. 1998;273:17793–17800.
   PubMed Web of Science ®Google Scholar
• Chiesa G, Hobbs HH, Koschinsky ML, et al. Reconstitution of lipoprotein(a) by infusion of human low density lipoprotein into transgenic mice expressing human apolipoprotein(a). J Biol Chem. 1992;267:24369–24374.
   PubMed Web of Science ®Google Scholar
• Frischmann ME, Ikewaki K, Trenkwalder E, et al. In vivo stable-isotope kinetic study suggests intracellular assembly of lipoprotein(a) ). Atherosclerosis. 2012;225:322–327.
   PubMed Web of Science ®Google Scholar
• White AL, Lanford RE. Cell surface assembly of lipoprotein(a) in primary cultures of baboon hepatocytes. J Biol Chem. 1994;269:28716–28723.
   PubMed Web of Science ®Google Scholar
• Tam SP, Zhang X, Koschinsky ML. Interaction of a recombinant form of apolipoprotein[a] with human fibroblasts and with the human hepatoma cell line HepG2. J Lipid Res. 1996;37:518–533.
   PubMed Web of Science ®Google Scholar
• Diffenderfer MR, Lamon-Fava S, Marcovina SM, et al. Distinct metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein(a). Metab Clin Exp. 2016;65:381–390.
   PubMed Web of Science ®Google Scholar
• Ooi EM, Watts GF, Chan DC, et al. Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2015;35:2686–2693.
   PubMed Web of Science ®Google Scholar
• Demant T, Seeberg K, Bedynek A, et al. The metabolism of lipoprotein(a) and other apolipoprotein B-containing lipoproteins: a kinetic study in humans. Atherosclerosis. 2001;157:325–339.
   PubMed Web of Science ®Google Scholar
• Reyes-Soffer G, Ginsberg HN, Ramakrishnan R. The metabolism of lipoprotein (a): an ever-evolving story. J Lipid Res. 2017;58:1756–1764.
   PubMed Web of Science ®Google Scholar
• Koschinsky ML, Boffa MB. Lipoprotein(a): an important cardiovascular risk factor and a clinical conundrum. Endocrinol Metab Clin North Am. 2014;43:949–962.
   PubMed Web of Science ®Google Scholar
• Rader DJ, Cain W, Ikewaki K, et al. The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest. 1994;93:2758–2763.
   PubMed Web of Science ®Google Scholar
• Cain WJ, Millar JS, Himebauch AS, et al. Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]. J Lipid Res. 2005;46:2681–2691.
   PubMed Web of Science ®Google Scholar
• Ye SQ, Keeling J, Stein O, et al. Tissue distribution of [3H]cholesteryl linoleyl ether-labeled human Lp(a) in different rat organs. Biochim Biophys Acta. 1988;963:534–540.
   PubMedGoogle Scholar
• Kostner KM, Clodi M, Bodlaj G, et al. Decreased urinary apolipoprotein (a) excretion in patients with impaired renal function. Eur J Clin Invest. 1998;28:447–452.
   PubMed Web of Science ®Google Scholar
• Kronenberg F, Kuen E, Ritz E, et al. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol. 2000;11:105–115.
   PubMed Web of Science ®Google Scholar
• Frank S, Hrzenjak A, Blaschitz A, et al. Role of various tissues in apo(a) fragmentation and excretion of fragments by the kidney. Eur J Clin Invest. 2001;31:504–512.
   PubMed Web of Science ®Google Scholar
• Khera AV, Everett BM, Caulfield MP, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). Circulation. 2014;129:635–642.
   PubMed Web of Science ®Google Scholar
• Slunga L, Johnson O, Dahlen GH. Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin. Eur J Clin Pharmacol. 1992;43:369–373.
   PubMed Web of Science ®Google Scholar
• Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med. 2001;5:378–387.
   PubMed Web of Science ®Google Scholar
• Hofmann SL, Eaton DL, Brown MS, et al. Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice. J Clin Invest. 1990;85:1542–1547.
   PubMed Web of Science ®Google Scholar
• Tsimikas S. Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk. Curr Opin Endocrinol Diabetes Obes. 2016;23:157–164.
   PubMed Web of Science ®Google Scholar
• Toth PP. PCSK9 and lipoprotein(a): the plot thickens. Circ Res. 2016;119:3–6.
   PubMed Web of Science ®Google Scholar
• Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154–156.
   PubMed Web of Science ®Google Scholar
• Romagnuolo R, Scipione CA, Boffa MB, et al. Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor. J Biol Chem. 2015;290:11649–11662.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Giugliano RP, Sabatine MS, et al. PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. J Lipid Res. 2016;57:1086–1096.
   PubMed Web of Science ®Google Scholar
• Desai NR, Kohli P, Giugliano RP, et al. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Circulation. 2013;128:962–9.
   PubMed Web of Science ®Google Scholar
• Romagnuolo R, Scipione CA, Marcovina SM, et al. Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9. PLoS One. 2017;12:e0180869.
   PubMed Web of Science ®Google Scholar
• Marz W, Beckmann A, Scharnagl H, et al. Heterogeneous lipoprotein (a) size isoforms differ by their interaction with the low density lipoprotein receptor and the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. FEBS Lett. 1993;325:271–275.
   PubMed Web of Science ®Google Scholar
• Argraves KM, Kozarsky KF, Fallon JT, et al. The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor. J Clin Invest. 1997;100:2170–2181.
   PubMed Web of Science ®Google Scholar
• Moriarty PM, Varvel SA, Gordts PL, et al. Lipoprotein(a) mass levels increase significantly according to APOE genotype: an analysis of 431 239 Patients. Arterioscler Thromb Vasc Biol. 2017;37:580–588.
   PubMed Web of Science ®Google Scholar
• Mack S, Coassin S, Rueedi R, et al. A genome-wide association meta-analysis on lipoprotein(a) concentrations adjusted for apolipoprotein(a) isoforms. J Lipid Res. 2017;58:1834–1844.
   PubMed Web of Science ®Google Scholar
• Yang XP, Amar MJ, Vaisman B, et al. Scavenger receptor-BI is a receptor for lipoprotein(a). J Lipid Res. 2013;54:2450–2457.
   PubMed Web of Science ®Google Scholar
• Sharma M, Von Zychlinski-Kleffmann A, Porteous CM, et al. Lipoprotein (a) upregulates ABCA1 in liver cells via scavenger receptor-B1 through its oxidized phospholipids. J Lipid Res. 2015;56:1318–1328.
   PubMed Web of Science ®Google Scholar
• Andronicos NM, Chen EI, Baik N, et al. Proteomics-based discovery of a novel, structurally unique, and developmentally regulated plasminogen receptor, Plg-RKT, a major regulator of cell surface plasminogen activation. Blood. 2010;115:1319–1330.
   PubMed Web of Science ®Google Scholar
• Sharma M, Redpath GM, Williams MJ, et al. Recycling of apolipoprotein(a) after PlgRKT-mediated endocytosis of lipoprotein(a). Circ Res. 2017;120:1091–1102.
   PubMed Web of Science ®Google Scholar
• Mackinnon LT, Hubinger L, Lepre F. Effects of physical activity and diet on lipoprotein(a). Med Sci Sports Exerc. 1997;29:1429–1436.
   PubMed Web of Science ®Google Scholar
• Yoshida H, Shoda T, Yanai H, et al. Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia. Atherosclerosis. 2013;J26:161–164.
   Google Scholar
• Yeang C, Hung MY, Byun YS, et al. Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a). J Clin Lipidol. 2016;10:594–603.
   PubMed Web of Science ®Google Scholar
• Santos RD, Raal FJ, Catapano AL, et al. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler Thromb Vasc Biol. 2015;35:689–699.
   PubMed Web of Science ®Google Scholar
• Samaha FF, McKenney J, Bloedon LT, et al. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med. 2008;5:497–505.
   PubMedGoogle Scholar
• Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363:2406–2415.
   PubMed Web of Science ®Google Scholar
• Thomas T, Zhou H, Karmally W, et al. CETP (cholesteryl ester transfer protein) inhibition with anacetrapib decreases production of lipoprotein(a) in mildly hypercholesterolemic subjects. Arterioscler Thromb Vasc Biol. 2017;37:1770–1775.
   PubMed Web of Science ®Google Scholar
• Stein EA, Raal F. Future directions to establish lipoprotein(a) as a treatment for atherosclerotic cardiovascular disease. Cardiovasc Drugs Ther. 2016;30:101–108.
   PubMed Web of Science ®Google Scholar
• Stein EA, Davidson MH, Dujovne CA, et al. Efficacy and tolerability of low-dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia: a prospective trial. J Cardiovasc Pharmacol Ther. 1996;1:107–116.
   PubMedGoogle Scholar
• Capuzzi DM, Guyton JR, Morgan JM, et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol. 1998;82:74U–81U.
   PubMed Web of Science ®Google Scholar
• Chennamsetty I, Kostner KM, Claudel T, et al. Nicotinic acid inhibits hepatic apoA gene expression: studies in humans and in transgenic mice. J Lipid Res. 2012;53:2405–2412.
   PubMed Web of Science ®Google Scholar
• Graham MJ, Viney N, Crooke RM, et al. Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans. J Lipid Res. 2016;57:340–351.
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Viney NJ, Hughes SG, et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet. 2015;386:1472–1483.
   PubMed Web of Science ®Google Scholar
• Viney NJ, van Capelleveen JC, Geary RS, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet. 2016;388:2239–2253.
   PubMed Web of Science ®Google Scholar
• Roeseler E, Julius U, Heigl F, et al. Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: prospective 5 years of follow-up and apolipoprotein(a) characterization. Arterioscler Thromb Vasc Biol. 2016;36:2019–2027.
   PubMed Web of Science ®Google Scholar
• Pokrovsky SN, Afanasieva OI, Ezhov MV. Lipoprotein(a) apheresis. Curr Opin Lipidol. 2016;27:351–358.
   PubMed Web of Science ®Google Scholar
• Safarova MS, Ezhov MV, Afanasieva OI, et al. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atheroscler Suppl. 2013;14:93–99.
   PubMed Web of Science ®Google Scholar
• McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59:2344–2353.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (Rutherford-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:331–340.
   PubMed Web of Science ®Google Scholar
• Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012;367:1891–1900.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Giugliano RP, Sabatine MS, et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol. 2014;63:1278–1288.
   PubMed Web of Science ®Google Scholar
• Gaudet D, Kereiakes DJ, McKenney JM, et al. Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). Am J Cardiol. 2014;14:711–715.
   Google Scholar
• Hegele RA, Gidding SS, Ginsberg HN, et al. Nonstatin low-density lipoprotein-lowering therapy and cardiovascular risk reduction-statement from ATVB council. Arterioscler Thromb Vasc Biol. 2015;35:2269–2280.
   PubMed Web of Science ®Google Scholar